高级检索
当前位置: 首页 > 详情页

The biology of medicinal resource substitution in Salvia

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China [2]Shandong Acad Chinese Med, Cent Lab, Jinan 250014, Peoples R China [3]Sichuan Acad Tradit Chinese Med Sci, Sichuan Prov Key Lab Qual & Innovat Res Chinese M, Chengdu 610041, Sichuan, Peoples R China [4]Guangzhou Univ Chinese Med, Clin Coll 2, Key Lab Qual Evaluat Chinese Med, Guangdong Prov Med Prod Adm, Guangzhou, Peoples R China
出处:
ISSN:

关键词: Alternative species Ecology Medicinal resource substitution Phylogeny Salvia

摘要:
Background The decrease of wild reserves and the sharp increase of market demand have led to resource substitution, but it is still not clear how to discover medicinal alternative resources. Here we reveal the biology of medicinal resource substitution in the case of Salvia. Methods A hypothesis was put forward that phylogeny and ecology were the main factors which determined alternative species selection. Phylogenetic analysis was performed based on chloroplast genomes. Spatial climatic pattern was assessed through three mathematical models. Results Salvia miltiorrhiza and alternative species were mainly located in Clade 3 in topology, and their growth environment was clustered into an independent group 3 inferred from principal component analysis. Correlation and Maxent major climate factor analyses showed that the ecological variations within each lineage were significantly smaller than the overall divergent between any two lineages. Mantel test reconfirmed the inalienability between phylogeny and ecology (P = 0.002). Only the species that are genetically and ecologically related to S. miltiorrhiza can form a cluster with it. Conclusions Phylogenetic relationship and geographical climate work together to determine which species has the potential to be selected as substitutes. Other medicinal plants can learn from this biology towards developing alternative resources.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 3 区 全科医学与补充医学 4 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 全科医学与补充医学 2 区 药学
JCR分区:
出版当年[2019]版:
Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China [2]Shandong Acad Chinese Med, Cent Lab, Jinan 250014, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号